Andy Chen
Stock Analyst at Wolfe Research
(0.81)
# 3,551
Out of 4,805 analysts
33
Total ratings
26.09%
Success rate
-17.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Initiates: Outperform | n/a | $16.24 | - | 1 | Feb 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Peer Perform | n/a | $26.85 | - | 1 | Feb 4, 2025 | |
| ETNB 89bio | Initiates: Outperform | n/a | $5.00 | - | 1 | Feb 4, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $20 | $7.37 | +171.37% | 1 | Feb 4, 2025 | |
| VERA Vera Therapeutics | Initiates: Outperform | $49 | $21.81 | +124.67% | 1 | Feb 4, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $19 | $6.78 | +180.24% | 1 | Feb 4, 2025 | |
| IMVT Immunovant | Downgrades: Peer Perform | n/a | $14.79 | - | 2 | Jan 3, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $697 | $546.22 | +27.60% | 2 | Nov 12, 2024 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Underperform | n/a | $226.28 | - | 2 | Nov 12, 2024 | |
| INCY Incyte | Initiates: Outperform | n/a | $55.17 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $15.94 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $33.97 | - | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $22.40 | +190.18% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $34.82 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $307.35 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.41 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $0.85 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $26.71 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $34.26 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $9.65 | +76.17% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $6.77 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $475.49 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $64.81 | -35.20% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $60 | $0.63 | +9,484.66% | 1 | Aug 8, 2023 |
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $16.24
Upside: -
Crinetics Pharmaceuticals
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $26.85
Upside: -
89bio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $5.00
Upside: -
Oruka Therapeutics
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $7.37
Upside: +171.37%
Vera Therapeutics
Feb 4, 2025
Initiates: Outperform
Price Target: $49
Current: $21.81
Upside: +124.67%
Zenas BioPharma
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $6.78
Upside: +180.24%
Immunovant
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $14.79
Upside: -
argenx SE
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $546.22
Upside: +27.60%
Alnylam Pharmaceuticals
Nov 12, 2024
Downgrades: Underperform
Price Target: n/a
Current: $226.28
Upside: -
Incyte
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $55.17
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $15.94
Upside: -
Aug 26, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $33.97
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $22.40
Upside: +190.18%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $34.82
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $307.35
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $11.41
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $0.85
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $26.71
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $34.26
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $9.65
Upside: +76.17%
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $6.77
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $475.49
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $64.81
Upside: -35.20%
Aug 8, 2023
Assumes: Buy
Price Target: $60
Current: $0.63
Upside: +9,484.66%